Last 81.00 GBp
Change Today 0.00 / 0.00%
Volume 891.0K
VEC On Other Exchanges
Symbol
Exchange
London
OTC US
Frankfurt
As of 11:35 AM 06/19/13 All times are local (Market data is delayed by at least 15 minutes).

vectura group plc (VEC) Snapshot

Open
80.75 GBp
Previous Close
81.00 GBp
Day High
83.00 GBp
Day Low
80.75 GBp
52 Week High
02/19/13 - 97.75 GBp
52 Week Low
07/18/12 - 65.00 GBp
Market Cap
271.6M
Average Volume 10 Days
284.2K
EPS TTM
-0.02 GBp
Shares Outstanding
335.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VECTURA GROUP PLC (VEC)

Related News

No related news articles were found.

vectura group plc (VEC) Related Businessweek News

No Related Businessweek News Found

vectura group plc (VEC) Details

Vectura Group plc develops inhaled therapies primarily for the treatment of respiratory diseases. Its products target various diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The company offers ADVATE, a serum-free recombinant factor VIII for haemophilia A; Adept, a 4% icodextrin solution used during surgery to reduce post-surgical adhesions; and Extraneal, a solution containing icodextrin for peritoneal dialysis, as well as Asmasal Clickhaler, Asmabec Clickhaler, Meptin Clickhaler, budesonide Clickhaler, and formoterol Clickhaler for the treatment of asthma. Its product pipeline comprises NVA237 and QVA149 for COPD; VR315, VR632, and VR506 for the treatment of asthma/COPD; VR496 for the treatment of Cystic fibrosis; and VR040 for the treatment of Parkinson’s disease. The company also provides various drug delivery technology platforms, such as PowderHale, a dry powder inhalation (DPI) formulation technology that is designed to allow aerosolized drug particles to achieve high lung deposition with low-dose variability; GyroHaler and OmniHaler, the multi-unit dose DPI devices, which are designed to deliver locally acting drugs to the lungs; and Duohaler, a two reservoir DPI. It has development collaborations and license agreements with Novartis, Sandoz, Baxter, and GlaxoSmithKline. The company was founded in 1997 and is headquartered in Chippenham, the United Kingdom.

Founded in 1997

vectura group plc (VEC) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 502.0K GBP
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: 334.0K GBP
Compensation as of Fiscal Year 2012.

vectura group plc (VEC) Key Developments

Vectura Group plc Announces Executive Changes, Effective July 1, 2013

Vectura Group plc announced that Anne Hyland is stepping down from her board position and as CFO and Company Secretary at the end of June. Paul Oliver, currently Financial Controller, will be appointed to the board as CFO and Company Secretary from July 1, 2013. Paul joined Vectura in 2006 and has managed Vectura's finances for the last seven years. In his role as Group Financial Controller, Paul has worked closely with Anne, Vectura's Leadership Team and the Board on all aspects of Vectura's operations and strategy development. Prior to joining Vectura, Paul worked in professional practice and is a Fellow of the Association of Chartered Certified Accountants.

Vectura Group plc Reports Unaudited Consolidated Earnings Results for the Year Ended March 31, 2013; Provides Capital Expenditure Guidance for the Fiscal Year 2014

Vectura Group plc reported unaudited consolidated earnings results for the year ended March 31, 2013. For the year, the company reported operating loss of £11.6 million, loss before taxation of £10.4 million, loss after taxation attributable to equity holders of the company and total comprehensive income of £5.9 million or 1.8 pence loss per share on revenue of £30.5 million against operating loss of £13.9 million, loss before taxation of £13.2 million, loss after taxation attributable to equity holders of the company and total comprehensive income of £4.4 million or 1.3 pence loss per share on revenue of £33.0 million for the same period a year ago. Net cash outflow from operating activities of £2.8 million against net cash inflow from operating activities of £2.1 million for the same period a year ago. EBITDA loss improves to £3.4 million from £4.2 million for the same period a year ago. The revenue was lower as a result of lower pharmaceutical development service revenues and device sales this year, but were ahead of expectations. The EBITDA loss improvement is mainly due to a 5% increase in gross margin and a 6% reduction in research and development expenditure to £30.9 million against £32.8 million for the same period a year ago. Capital expenditure was just under £4 million. The company expects the assets to be amortized over the next 3 years, with a charge in 2014 to be in line with the charge the company incurred last year at about £6.3 million. The company expects capital expenditure to be in line with last year.

Vectura Group plc Presents at Jefferies 2013 Global Healthcare Conference, Jun-06-2013 08:00 AM

Vectura Group plc Presents at Jefferies 2013 Global Healthcare Conference, Jun-06-2013 08:00 AM. Venue: Grand Hyatt Hotel, 109 East 42nd Street at Grand Central, New York, New York, United States. Speakers: Christopher Paul Blackwell, Chief Executive Officer and Executive Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VEC:LN 81.00 GBp 0.00

VEC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergy Therapeutics PLC 9.88 GBp 0.00
Enzon Pharmaceuticals Inc $1.70 USD 0.00
GW Pharmaceuticals PLC 47.25 GBp +1.50
Sinclair IS Pharma PLC 26.88 GBp +0.125
Vernalis PLC 21.75 GBp 0.00
View Industry Companies
 

Industry Analysis

VEC

Industry Average

Valuation VEC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.1x
Price/Book 2.1x
Price/Cash Flow 698.7x
TEV/Sales 9.1x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VECTURA GROUP PLC, please visit www.vectura.co.uk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.